JOURNAL OF BIOENERGETICS AND BIOMEMBRANES-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1223201, encodeId=a8f4122320177, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫 经验分享：审稿人友好，审稿速度快，影响因子呈上升态势，希望能保持。我近期一篇文章审稿进程如下，给大家参考 2022.4.4 Quality check in progress 2022.4.5 Editor appointed 2022.4.7 8 reviewers invited 2022.4.7 1 Reviewer(s) accepted 2022.4.9 2Reviewer(s) accepted 2022.4.23 1reviewer report received 2022.4.27 decision of ms (revise) 2022.5.9 resubmit ms 2022.5.11 Editor evaluating revision 2022.5.25 accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee4a1669911, createdName=medfg, createdTime=Sun May 29 18:09:05 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092585, encodeId=01f910925851b, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092586, encodeId=4368109258654, content=什么是SCI？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539992, encodeId=537f539992c9, content=有所上涨，看好未来，大家认为呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yang_guoqiang2010, createdTime=Tue Jul 18 18:37:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=492406, encodeId=c960492406ad, content=明年能不能冲到3分？大家谈谈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=442, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qupeter, createdTime=Wed Nov 28 16:24:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]

2022-05-29 medfg

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：免疫
经验分享：审稿人友好，审稿速度快，影响因子呈上升态势，希望能保持。我近期一篇文章审稿进程如下，给大家参考
2022.4.4 Quality check in progress
2022.4.5 Editor appointed
2022.4.7 8 reviewers invited
2022.4.7 1 Reviewer(s) accepted
2022.4.9 2Reviewer(s) accepted
2022.4.23 1reviewer report received
2022.4.27 decision of ms (revise)
2022.5.9 resubmit ms
2022.5.11 Editor evaluating revision
2022.5.25 accepted

23 0

[GetPortalCommentsPageByObjectIdResponse(id=1223201, encodeId=a8f4122320177, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫 经验分享：审稿人友好，审稿速度快，影响因子呈上升态势，希望能保持。我近期一篇文章审稿进程如下，给大家参考 2022.4.4 Quality check in progress 2022.4.5 Editor appointed 2022.4.7 8 reviewers invited 2022.4.7 1 Reviewer(s) accepted 2022.4.9 2Reviewer(s) accepted 2022.4.23 1reviewer report received 2022.4.27 decision of ms (revise) 2022.5.9 resubmit ms 2022.5.11 Editor evaluating revision 2022.5.25 accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee4a1669911, createdName=medfg, createdTime=Sun May 29 18:09:05 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092585, encodeId=01f910925851b, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092586, encodeId=4368109258654, content=什么是SCI？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539992, encodeId=537f539992c9, content=有所上涨，看好未来，大家认为呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yang_guoqiang2010, createdTime=Tue Jul 18 18:37:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=492406, encodeId=c960492406ad, content=明年能不能冲到3分？大家谈谈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=442, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qupeter, createdTime=Wed Nov 28 16:24:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]

2021-12-29 Gym璨烨

如果文章发表了未提供ORCIDID如何添加？

41 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1223201, encodeId=a8f4122320177, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫 经验分享：审稿人友好，审稿速度快，影响因子呈上升态势，希望能保持。我近期一篇文章审稿进程如下，给大家参考 2022.4.4 Quality check in progress 2022.4.5 Editor appointed 2022.4.7 8 reviewers invited 2022.4.7 1 Reviewer(s) accepted 2022.4.9 2Reviewer(s) accepted 2022.4.23 1reviewer report received 2022.4.27 decision of ms (revise) 2022.5.9 resubmit ms 2022.5.11 Editor evaluating revision 2022.5.25 accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee4a1669911, createdName=medfg, createdTime=Sun May 29 18:09:05 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092585, encodeId=01f910925851b, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092586, encodeId=4368109258654, content=什么是SCI？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539992, encodeId=537f539992c9, content=有所上涨，看好未来，大家认为呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yang_guoqiang2010, createdTime=Tue Jul 18 18:37:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=492406, encodeId=c960492406ad, content=明年能不能冲到3分？大家谈谈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=442, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qupeter, createdTime=Wed Nov 28 16:24:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]

2021-12-29 MS68862005

什么是SCI？

0 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1223201, encodeId=a8f4122320177, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫 经验分享：审稿人友好，审稿速度快，影响因子呈上升态势，希望能保持。我近期一篇文章审稿进程如下，给大家参考 2022.4.4 Quality check in progress 2022.4.5 Editor appointed 2022.4.7 8 reviewers invited 2022.4.7 1 Reviewer(s) accepted 2022.4.9 2Reviewer(s) accepted 2022.4.23 1reviewer report received 2022.4.27 decision of ms (revise) 2022.5.9 resubmit ms 2022.5.11 Editor evaluating revision 2022.5.25 accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee4a1669911, createdName=medfg, createdTime=Sun May 29 18:09:05 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092585, encodeId=01f910925851b, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092586, encodeId=4368109258654, content=什么是SCI？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539992, encodeId=537f539992c9, content=有所上涨，看好未来，大家认为呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yang_guoqiang2010, createdTime=Tue Jul 18 18:37:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=492406, encodeId=c960492406ad, content=明年能不能冲到3分？大家谈谈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=442, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qupeter, createdTime=Wed Nov 28 16:24:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]

2017-07-18 yang_guoqiang2010

有所上涨，看好未来，大家认为呢？

203 0

[GetPortalCommentsPageByObjectIdResponse(id=1223201, encodeId=a8f4122320177, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：免疫 经验分享：审稿人友好，审稿速度快，影响因子呈上升态势，希望能保持。我近期一篇文章审稿进程如下，给大家参考 2022.4.4 Quality check in progress 2022.4.5 Editor appointed 2022.4.7 8 reviewers invited 2022.4.7 1 Reviewer(s) accepted 2022.4.9 2Reviewer(s) accepted 2022.4.23 1reviewer report received 2022.4.27 decision of ms (revise) 2022.5.9 resubmit ms 2022.5.11 Editor evaluating revision 2022.5.25 accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee4a1669911, createdName=medfg, createdTime=Sun May 29 18:09:05 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092585, encodeId=01f910925851b, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092586, encodeId=4368109258654, content=什么是SCI？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539992, encodeId=537f539992c9, content=有所上涨，看好未来，大家认为呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=yang_guoqiang2010, createdTime=Tue Jul 18 18:37:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=492406, encodeId=c960492406ad, content=明年能不能冲到3分？大家谈谈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=442, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qupeter, createdTime=Wed Nov 28 16:24:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]

2012-11-28 qupeter

明年能不能冲到3分？大家谈谈

442 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务